Long-term Pulmonary Safety of Inhaled Levodopa in Parkinson's Disease Subjects with Motor Fluctuations: A Phase 3 Open-label Randomized Study

被引：0
|
作者：
Grosset, Donald
Dhall, Rohit
Gurevich, Tanya
Kassubek, Jan
Poewe, Werner
Rascol, Olivier
Rudzinska, Monika
Cormier, Jennifer
Sedkov, Alexander
Oh, Charles
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
190
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [41] A long-term, open-label extension study to investigate the long-term safety of alogliptin in subjects with type 2 diabetes
    Smith, N.
    Pratley, R.
    Wilson, C.
    Mekki, Q.
    DIABETOLOGIA, 2017, 60 : S357 - S358
  • [42] Effect of Prasinezumab on Parkinson's disease (PD) Motor Progression in a Long-term Open-label Extension of the PASADENA Trial
    Pagano, G.
    Monnet, A.
    Reyes, A.
    Ribba, B.
    Svoboda, H.
    Kustermann, T.
    Simuni, T.
    Postuma, R.
    Pavese, N.
    Stocchi, F.
    Brockmann, K.
    Smigorski, K.
    Gerbaldo, V.
    Fontoura, P.
    Doody, R.
    Kerchner, G.
    Brundin, P.
    Marek, K.
    Bonni, A.
    Nikolcheva, T.
    MOVEMENT DISORDERS, 2024, 39 : S346 - S347
  • [43] Long-Term Efficacy and Safety of Pramipexole Extended-Release in Advanced Parkinson's Disease: An Open-Label Trial
    Schapira, Anthony
    Barone, Paolo
    Hauser, Robert
    Mizuno, Youshikuni
    Rascol, Olivier
    Busse, Michael
    Salin, Laurence
    Sohr, Mandy
    Poewe, Werner
    NEUROLOGY, 2010, 74 (09) : A349 - A350
  • [44] A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia
    Naoki Kashihara
    Yoshimitsu Yamasaki
    Takeshi Osonoi
    Hiromasa Harada
    Yugo Shibagaki
    June Zhao
    Hyosung Kim
    Toshitaka Yajima
    Nobuaki Sarai
    Clinical and Experimental Nephrology, 2021, 25 : 140 - 149
  • [45] A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia
    Kashihara, Naoki
    Yamasaki, Yoshimitsu
    Osonoi, Takeshi
    Harada, Hiromasa
    Shibagaki, Yugo
    Zhao, June
    Kim, Hyosung
    Yajima, Toshitaka
    Sarai, Nobuaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (02) : 140 - 149
  • [46] Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson's disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial
    Chang, H. J.
    Park, J.
    Oh, S.
    Shin, C. W.
    Cho, J. W.
    Lee, J. Y.
    MOVEMENT DISORDERS, 2022, 37 : S321 - S321
  • [47] An interim analysis of an open-label extension study to examine the long-term safety and tolerability of pimavanserin in the treatment of Parkinson's disease psychosis
    Mills, R.
    Bahr, D.
    Williams, H.
    Peters, P.
    Isaacson, S.
    MOVEMENT DISORDERS, 2010, 25 (07) : S302 - S302
  • [48] Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)
    Boada, Merce
    Neve, Anuja
    Das, Bibha
    Wojtowicz, Jakub
    Huang, Zhiyue
    Bullain, Szofia
    Watkin, Michelle
    Lott, Dominik
    Bittner, Tobias
    Delmar, Paul
    Klein, Gregory
    Hofmann, Carsten
    Kerchner, Geoffrey A.
    Smith, Janice
    Baudler, Monika
    Fontoura, Paulo
    Doody, Rachelle S.
    JOURNAL OF ALZHEIMERS DISEASE, 2025, 103 (02) : 528 - 541
  • [49] An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)
    Costabel, Ulrich
    Albera, Carlo
    Lancaster, Lisa H.
    Lin, Chin-Yu
    Hormel, Philip
    Hulter, Henry N.
    Noble, Paul W.
    RESPIRATION, 2017, 94 (05) : 408 - 415
  • [50] Istradefylline, an adenosine A2A receptor antagonist, as adjunct to levodopa in Parkinson's disease (PD): A safety nalysis of 8 randomized controlled trials and 4 open-label long-term studies
    Hattori, N.
    Stocchi, F.
    Sethi, K.
    Ohta, E.
    Salzman, P. M.
    Mori, A.
    Toyama, K.
    Pahwa, R.
    MOVEMENT DISORDERS, 2019, 34 : S10 - S10
12345